Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy
Status
Conditions
Treatments
Details and patient eligibility
About
Optimal management of patients with locally advanced breast cancer remains a complex therapeutic problem. Newly diagnosed breast cancers in the United States with a higher incidence in medically underserved areas. The optimal intensity and duration of neoadjuvant chemotherapy still remains controversial due to the difficulty of evaluating response to therapy. The goal would be to prevent over and under treatment of patients with neoadjuvant chemotherapy.
Full description
The Researcher developed a diagnostic device called Diffuse Optical Spectroscopy Imaging is a non-invasive optical technique that utilizes intensity-modulated, near-infrared light to quantitatively measure optical properties in thick tissues.
Diffuse Optical Spectroscopy Imaging can images tissue hemoglobin , oxygen saturation, blood volume fraction, water content, fat content and cellular structure. The measurements provide quantitative optical property values that reflect changes in tissue perfusion, oxygen consumption, and cell/matrix development.
There is no therapeutic benefit to the subject, especially none that might influence the indication for the diagnostic procedure as indicated. However, information obtained may lead to a new form of non-invasive imaging for the early detection of breast cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Female non-pregnant and age greater than or equal to 21 years old but less than 75 years old
- Diagnosed with breast cancer and will be receiving neoadjuvant chemotherapy
Exclusion criteria
- Female pregnant and age less than 21 years old and have no diagnosis of breast cancer
Trial design
77 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal